nr

Tat-NR2B9c (NA-1) is a postsynaptic density-95 (PSD-95) inhibitor with neuroprotective and antiepileptic effects.Tat-NR2B9c inhibits PSD-95d2, PSD-95d1, and PSD-95, which prevents the activation of NMDA-induced NADPH oxidase in neurons, thereby blocking the production of superoxide, which reduces ischemic injury in the acute phase after stroke.

Tat-NR2B9c TFA is a 20-aa peptide, and acts as an inhibitor of postsynaptic density-95 (PSD-95)(EC50 of 6.7 nM for PSD-95d2), and possesses neuroprotective efficacy.

Tat-NR2B9c acetate (NA-1 acetate) is a postsynaptic density-95 (PSD-95) inhibitor, with EC50 values of 6.7 nM and 670 nM for PSD-95d2 (PSD-95 PDZ domain 2) and PSD-95d1, respectively. Tat-NR2B9c acetate disrupts the PSD-95/NMDAR interaction, inhibiting NR2A and NR2B binding to PSD-95 with IC50 values of 0.5 μM and 8 μM, respectively. Tat-NR2B9c acetate also inhibits neuronal nitric oxide synthase (nNOS)/PSD-95 interaction, and possesses neuroprotective efficacy.

Tat-NR2BAA is an inactive control peptide of Tat-NR2B9c. It shares a similar sequence with Tat-NR2B9c, but possesses a double-point mutation in the COOH terminal tSXV motif. This mutation renders Tat-NR2BAA unable to bind PSD-95. Tat-NR2B9c, on the other hand, is a membrane-permeable peptide that interferes with PSD-95/NMDAR binding. This interference leads to the decoupling of NR2B- and/or NR2A-type NMDARs from PSD-95[1][2].

SRC-1 NR box peptide acetate is a bioactive peptide, consisting of a 14-amino acid fragment derived from the steroid receptor coactivator SRC-1 NR II. This compound is useful for investigating the regulatory mechanisms of estrogen receptor ligands.

Tat-NR2BAA TFA serves as the inactive control peptide for Tat-NR2B9c, featuring a comparable sequence with a crucial distinction: a double-point mutation in its COOH-terminal tSXV motif. This alteration renders Tat-NR2BAA TFA unable to bind to PSD-95, in contrast to Tat-NR2B9c. The latter is a membrane-permeant peptide that impedes PSD-95/NMDAR interaction, specifically detaching NR2B- and/or NR2A-type NMDARs from PSD-95 [1].

Tat-HA-NR2B9, comprising an HIV-1 Tat transduction domain fragment, an influenza virus hemagglutinin (HA) epitope-tag, and the C-terminal 9 amino acids of NR2B (NR2B9c), has demonstrated efficacy in reducing infarct size and enhancing neurological function following ischemia-induced cerebral injury in rats [1].

GnRH Associated Peptide (GAP) (1-13), human Acetate was found to be a potent inhibitor of prolactin secretion and to stimulate the release of gonadotropins. Active immunization with peptides corresponding to GAP sequences led to greatly increased prolacti

Lanreotide, a somatostatin analogue, suppresses GH/IGF-I hypersecretion in acromegaly patients. It also used to manage neuroendocrine tumours.

Anrikefon (HSK21542) is a kappa opioid receptor agonist with analgesic effects.

Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist [1].

Mibenratide is a small cyclic peptide functioning as an adrenergic β1 receptor antagonist, primarily utilized in heart failure research [1].

sGnRH-A, a salmon gonadotropin-releasing hormone (GnRH) analogue, promotes growth hormone secretion and serves as an ovulation inducer for artificial insemination [1] [2].

sGnRH-A acetate, a salmon gonadotropin-releasing hormone (GnRH) analogue, stimulates growth hormone secretion and serves as an ovulation inducer for artificial insemination [1] [2].

Gonadotropin-Releasing Hormone-Associated Peptide (GAP) (25-53), Human, also known as hGAP-25-53, is a fragment of the human gonadotropin-releasing hormone-associated peptide that serves as an immunogen for producing antiseras such as MC-1, MC-2, and MC-3. This peptide is connected to the luteinizing hormone-releasing hormone (LH-RH) sequence through a 3 amino acid processing site [1].

Gonadotropin-Releasing Hormone-Associated Peptide (GAP) (1-24), human, also known as hGAP-1-24, is the 1-24 fragment of the human GAP, which is connected to the luteinizing hormone-releasing hormone (LH-RH) through a 3 amino acid processing site [1].

Lynronne-1, an antimicrobial peptide, exhibits activity against Gram-positive bacteria, including multi-drug resistant (MDR) strains, with a minimal inhibitory concentration (MIC) of 8-32 μg/mL for methicillin-resistant MRSA strains. Additionally, it effectively reduces the bacterial load in a murine model of MRSA-infected wounds and demonstrates efficacy against P. aeruginosa infections [1].

Lynronne-2, an antimicrobial peptide, exhibits activity against Gram-positive bacteria, including methicillin-resistant MRSA strains (MIC: 32-256 μg/mL), and demonstrates effectiveness in combating P. aeruginosa infections [1].

Lynronne-3, an antimicrobial peptide, demonstrates activity against Gram-positive bacteria, including multi-drug resistant (MDR) strains, with a minimum inhibitory concentration (MIC) ranging from 32-128 μg/mL for methicillin-resistant Staphylococcus aureus (MRSA) strains. Additionally, Lynronne-3 is efficacious in combating Pseudomonas aeruginosa infections [1].

NRC-16 is a biologically active peptide with characteristics similar to pleurocidin, a cationic antimicrobial peptide (cationic AMP).

Mibenratide TFA, a small cyclic peptide, functions as an adrenergic β1 receptor antagonist and has potential applications in heart failure research [1].

Lanreotide (BIM 23014) diTFA, a somatostatin analogue, exhibits antineoplastic activity and may be utilized in carcinoid syndrome research [1] [2].

Lanreotide acetate (BIM 23014 acetate) is a somatostatin analogue with antineoplastic activity, used for carcinoid syndrome

Icotrokinra is an orally bioavailable and highly selective antagonist of the interleukin-23 receptor (IL-23R), thereby interfering with IL-23-mediated signaling cascades. Icotrokinra inhibits IL-23-induced STAT3 phosphorylation in peripheral blood mononuclear cells with an IC50 value of 5.6 pM, and it suppresses IL-23-induced interferon-gamma production in natural killer cells with an IC50 value of 18.4 pM. Icotrokinra further demonstrates anti-inflammatory effects in a rat TNBS-induced colitis model, making it a compound of interest in the study of psoriasis, psoriatic arthritis, and inflammatory bowel disease.